Marjo S van der Knaap1, Nicole I Wolf1, Vivi M Heine1. 1. Department of Child Neurology (MSvdK, NIW, VMH), Amsterdam Neuroscience, VU University Medical Centre, Amsterdam; and Departments of Functional Genomics (MSvdK) and Complex Trait Genetics (VMH), Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University, Amsterdam, the Netherlands.
Abstract
PURPOSE OF REVIEW: Leukodystrophies are genetic disorders primarily and predominantly affecting CNS white matter. They are associated with connotations such as "much unknown," "progressive myelin loss," and "nothing can be done." Recent technological progress is reversing this picture. RECENT FINDINGS: Next-generation sequencing has created the revolution of whole-exome/genome sequencing, allowing disease definition and gene identification for numerous ultra-rare disorders by focusing on very small groups and individual patients. Knowledge of many new "white matter proteins" is transforming our understanding of white matter physiology and pathophysiology. Regarding therapy, especially stem cell and gene therapy are evolving rapidly, aiming at personalized therapy for a specific patient with a specific disease. Multimodal approaches targeting multiple aspects of the disease hold the highest promise. SUMMARY: Technological developments are revolutionizing the leukodystrophy field. Unknown becomes known and untreatable becomes treatable. New insight is that not all leukodystrophies are irreversible and that some improve spontaneously.
PURPOSE OF REVIEW: Leukodystrophies are genetic disorders primarily and predominantly affecting CNS white matter. They are associated with connotations such as "much unknown," "progressive myelin loss," and "nothing can be done." Recent technological progress is reversing this picture. RECENT FINDINGS: Next-generation sequencing has created the revolution of whole-exome/genome sequencing, allowing disease definition and gene identification for numerous ultra-rare disorders by focusing on very small groups and individual patients. Knowledge of many new "white matter proteins" is transforming our understanding of white matter physiology and pathophysiology. Regarding therapy, especially stem cell and gene therapy are evolving rapidly, aiming at personalized therapy for a specific patient with a specific disease. Multimodal approaches targeting multiple aspects of the disease hold the highest promise. SUMMARY: Technological developments are revolutionizing the leukodystrophy field. Unknown becomes known and untreatable becomes treatable. New insight is that not all leukodystrophies are irreversible and that some improve spontaneously.
Authors: Jacqueline A Hawkins-Salsbury; Lauren Shea; Xuntian Jiang; Daniel A Hunter; A Miguel Guzman; Adarsh S Reddy; Elizabeth Y Qin; Yedda Li; Steven J Gray; Daniel S Ory; Mark S Sands Journal: J Neurosci Date: 2015-04-22 Impact factor: 6.167
Authors: Adeline Vanderver; Morgan Prust; Davide Tonduti; Fanny Mochel; Heather M Hussey; Guy Helman; James Garbern; Florian Eichler; Pierre Labauge; Patrick Aubourg; Diana Rodriguez; Marc C Patterson; Johan L K Van Hove; Johanna Schmidt; Nicole I Wolf; Odile Boespflug-Tanguy; Raphael Schiffmann; Marjo S van der Knaap Journal: Mol Genet Metab Date: 2015-01-29 Impact factor: 4.797
Authors: Marjan E Steenweg; Nicole I Wolf; Jolanda H Schieving; Mahmoud Fawzi Elsaid; Richard L Friederich; John R Ostergaard; Frederik Barkhof; Petra J W Pouwels; Marjo S van der Knaap Journal: Arch Neurol Date: 2012-01
Authors: Björn M van Geel; Bwee Tien Poll-The; Aad Verrips; Jaap-Jan Boelens; Stephan Kemp; Marc Engelen Journal: J Inherit Metab Dis Date: 2014-12-09 Impact factor: 4.982
Authors: Christel Depienne; Marianna Bugiani; Céline Dupuits; Damien Galanaud; Valérie Touitou; Nienke Postma; Carola van Berkel; Emiel Polder; Eleonore Tollard; Frédéric Darios; Alexis Brice; Christine E de Die-Smulders; Johannes S Vles; Adeline Vanderver; Graziella Uziel; Cengiz Yalcinkaya; Suzanna G Frints; Vera M Kalscheuer; Jan Klooster; Maarten Kamermans; Truus Em Abbink; Nicole I Wolf; Frédéric Sedel; Marjo S van der Knaap Journal: Lancet Neurol Date: 2013-05-22 Impact factor: 44.182
Authors: Martje E van Egmond; Petra J W Pouwels; Jaap-Jan Boelens; Caroline A Lindemans; Frederik Barkhof; Martijn D Steenwijk; Peter M van Hasselt; Marjo S van der Knaap; Nicole I Wolf Journal: JAMA Neurol Date: 2013-06 Impact factor: 18.302
Authors: Seemin Seher Ahmed; Huapeng Li; Chunyan Cao; Elif M Sikoglu; Andrew R Denninger; Qin Su; Samuel Eaton; Ana A Liso Navarro; Jun Xie; Sylvia Szucs; Hongwei Zhang; Constance Moore; Daniel A Kirschner; Thomas N Seyfried; Terence R Flotte; Reuben Matalon; Guangping Gao Journal: Mol Ther Date: 2013-07-02 Impact factor: 11.454
Authors: Martha S Windrem; Marta C Nunes; William K Rashbaum; Theodore H Schwartz; Robert A Goodman; Guy McKhann; Neeta S Roy; Steven A Goldman Journal: Nat Med Date: 2003-12-21 Impact factor: 53.440
Authors: Hao Yin; Wen Xue; Sidi Chen; Roman L Bogorad; Eric Benedetti; Markus Grompe; Victor Koteliansky; Phillip A Sharp; Tyler Jacks; Daniel G Anderson Journal: Nat Biotechnol Date: 2014-03-30 Impact factor: 54.908
Authors: Vanessa Zanette; Aurelio Reyes; Mark Johnson; Daniel do Valle; Alan J Robinson; Vaneisse Monteiro; Bruno Augusto Telles; Ricardo L R Souza; Mara L S F Santos; Cristiane Benincá; Massimo Zeviani Journal: Neurol Genet Date: 2020-10-07
Authors: Prisca S Leferink; Stephanie Dooves; Anne E J Hillen; Kyoko Watanabe; Gerbren Jacobs; Lisa Gasparotto; Paulien Cornelissen-Steijger; Marjo S van der Knaap; Vivi M Heine Journal: Ann Neurol Date: 2019-09-10 Impact factor: 10.422
Authors: M Rogac; D Neubauer; L Leonardis; N Pecaric; M Meznaric; A Maver; W Sperl; B M Garavaglia; E Lamantea; B Peterlin Journal: Balkan J Med Genet Date: 2022-06-05 Impact factor: 0.810